FIELD: biotechnology.
SUBSTANCE: present invention relates to the field of biotechnology, in particular to new antisense oligonucleotides; it can be used in medicine. The invention discloses highly efficient modified oligonucleotide, which is capable of inhibiting the expression of mRNA of a hepatitis B virus surface antigen (HBsAg).
EFFECT: invention can be used in medical practice for the treatment of infections caused by hepatitis B virus (HBV).
25 cl, 19 dwg, 4 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CONJUGATES AND THEIR OBTAINING AND APPLICATION | 2018 |
|
RU2795400C2 |
| NUCLEIC ACID MOLECULES FOR REDUCING THE LEVEL OF PAPD5 OR PAPD7 MRNA FOR TREATING INFECTIOUS HEPATITIS B | 2017 |
|
RU2768699C2 |
| TREATMENT OF TUMORS OF DISEASES RELATED TO THE GENOM-SUPPRESSOR BY THERAPY OF NATURAL TRANSCRIPT INHIBITION IN ANTI-SIGNIFICANT ORIENTATION REGARDING THIS GENE | 2009 |
|
RU2746478C2 |
| MODIFIED OLIGONUCLEOTIDES AND METHODS OF THEIR USE | 2017 |
|
RU2802836C2 |
| AGENTS FOR RNAi, COMPOSITIONS AND METHODS OF THEIR USE FOR THE TREATMENT OF DISEASES ASSOCIATED WITH TRANSTHYRETIN (TTR) | 2012 |
|
RU2804776C2 |
| METHOD FOR CARRYING OUT DIAGNOSTIC ANALYSIS | 2001 |
|
RU2228530C2 |
| COMPOSITIONS AND METHODS FOR MODULATION OF HBV AND TTR EXPRESSION | 2014 |
|
RU2782034C2 |
| MIRNA STRUCTURES WITH HIGH ACTIVITY AND REDUCED EXPOSURE OUTSIDE THE TARGET | 2016 |
|
RU2788030C2 |
| NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF LPA IN CELL | 2018 |
|
RU2822093C1 |
| CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID MOLECULES THAT MEDIATE RNA INTERFERENCE | 2006 |
|
RU2418068C2 |
